Bausch Health Companies Inc (NYSE:BHC) Expected to Post Quarterly Sales of $2.16 Billion

Share on StockTwits

Equities analysts expect that Bausch Health Companies Inc (NYSE:BHC) will announce sales of $2.16 billion for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Bausch Health Companies’ earnings, with the highest sales estimate coming in at $2.20 billion and the lowest estimate coming in at $2.13 billion. Bausch Health Companies posted sales of $2.14 billion in the same quarter last year, which would indicate a positive year over year growth rate of 0.9%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, November 5th.

On average, analysts expect that Bausch Health Companies will report full year sales of $8.50 billion for the current financial year, with estimates ranging from $8.38 billion to $8.55 billion. For the next fiscal year, analysts expect that the firm will report sales of $8.78 billion, with estimates ranging from $8.47 billion to $9.30 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.03 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.03). Bausch Health Companies had a negative net margin of 10.88% and a positive return on equity of 52.12%. The firm had revenue of $2.15 billion during the quarter, compared to analysts’ expectations of $2.15 billion. During the same quarter last year, the company posted $0.93 EPS. The firm’s revenue was up 1.1% compared to the same quarter last year.

A number of equities research analysts have issued reports on the stock. Wells Fargo & Co reiterated a “sell” rating on shares of Bausch Health Companies in a research report on Monday, July 15th. ValuEngine upgraded shares of Bausch Health Companies from a “strong sell” rating to a “sell” rating in a research report on Monday, July 29th. JPMorgan Chase & Co. upgraded shares of Bausch Health Companies from an “underweight” rating to a “neutral” rating and set a $24.80 target price for the company in a research report on Monday, May 13th. Mizuho set a $45.00 target price on shares of Bausch Health Companies and gave the stock a “buy” rating in a research report on Thursday, June 20th. Finally, TD Securities upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Thursday. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $29.68.

In other news, EVP Christina Ackermann sold 3,968 shares of the stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $24.81, for a total transaction of $98,446.08. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 11.87% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in BHC. FIL Ltd grew its stake in Bausch Health Companies by 69.6% in the 1st quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock valued at $260,170,000 after buying an additional 4,327,851 shares during the last quarter. Vanguard Group Inc. grew its stake in Bausch Health Companies by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,513,863 shares of the company’s stock valued at $239,940,000 after buying an additional 363,579 shares during the last quarter. Bank of Montreal Can grew its stake in Bausch Health Companies by 43.7% in the 2nd quarter. Bank of Montreal Can now owns 5,318,505 shares of the company’s stock valued at $134,133,000 after buying an additional 1,616,428 shares during the last quarter. Renaissance Technologies LLC grew its stake in Bausch Health Companies by 9.8% in the 2nd quarter. Renaissance Technologies LLC now owns 3,037,200 shares of the company’s stock valued at $76,598,000 after buying an additional 272,000 shares during the last quarter. Finally, Clearbridge Investments LLC grew its stake in Bausch Health Companies by 0.5% in the 1st quarter. Clearbridge Investments LLC now owns 2,897,282 shares of the company’s stock valued at $71,563,000 after buying an additional 14,610 shares during the last quarter. Institutional investors own 53.70% of the company’s stock.

BHC stock traded up $0.42 during midday trading on Monday, reaching $21.30. The company had a trading volume of 2,662,200 shares, compared to its average volume of 3,134,013. Bausch Health Companies has a 1 year low of $17.20 and a 1 year high of $28.45. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 8.94. The company has a market capitalization of $7.42 billion, a P/E ratio of 5.30, a PEG ratio of 0.25 and a beta of 0.76. The company has a 50 day moving average of $23.72 and a two-hundred day moving average of $23.90.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Read More: What is the Beige Book?

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.